Biotech News

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Pasithea Therapeutics (KTTA)Pasithea Therapeutics2026-05-04 11:01 ESTCompany update

KTTA (KTTA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ktta.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

KTTAPasithea Therapeutics2026-07-21 11:00 EST

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

KTTAPasithea Therapeutics2026-07-08 11:02 EST

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

KTTAPasithea Therapeutics2026-06-30 11:00 EST

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

KTTAPasithea Therapeutics2026-06-15 11:02 EST

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

KTTAPasithea Therapeutics2026-06-02 11:02 EST

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

KTTAPasithea Therapeutics2026-04-20 11:01 EST

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

KTTAPasithea Therapeutics2026-04-01 11:01 EST

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

KTTAPasithea Therapeutics2026-02-17 12:01 EST

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

KTTAPasithea Therapeutics2026-01-13 12:01 EST

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

View all latest news

Pasithea Therapeutics

Pasithea Therapeutics is a biotechnology company focused on neuropsychiatric disorders and inflammation-linked biology. Its story centers on developing treatments for difficult CNS conditions with limited effective options.

Recent company news

KTTABruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

KTTAQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

KTTAMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

KTTAAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

KTTAGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 0.48 USD
Market cap: 21.55M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States